jRCT2041200093招募中不适用
Open-Label, Single-Arm, Multicenter Study to Evaluate Long-Term Safety and Tolerability of Brivaracetam Used as Adjunctive Treatment in Pediatric Study Participants With Epilepsy (An open-label, long-term safety and tolerability study of brivaracetam as adjunctive treatment in pediatric study participants with epilepsy)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 110
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Single Arm Study
- 干预模型
- Single Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- 1month old over 至 15age old under（—）
- 性别
- All
入选标准
- •Inclusion criteria for long-term follow-up (LTFU) study participants only
- •Study participants >=1 month of age with a confirmed diagnosis of epilepsy who participated in core study N01266 [NCT01364597] and/or N01349 [NCT03325439] and for whom a reasonable benefit from long-term administration of brivaracetam (BRV) is expected
- •Inclusion criteria for directly enrolled (DE) study participants only
- •Study participant is >= 1 month to < 16 years of age
- •Study participant has presence of an electroencephalogram (EEG) reading compatible with the diagnosis of focal epilepsy within the last 10 years
- •Study participant has uncontrolled partial-onset seizure (POS) after an adequate course of treatment (in the opinion of the Investigator) with at least 1 antiepileptic drug (AED)
- •Study participant had at least 1 POS during the 4-week Screening Period
- •Study participant is taking at least 1 AED. Vagal nerve stimulator will be counted as a
- •concomitant AED
排除标准
- •Exclusion criteria for all study participants
- •Study participant has, in the Investigator's opinion, severe medical, neurological, or psychiatric disorders or laboratory values, which may have an impact on the safety of the study participant.
- •Study participant has end-stage kidney disease requiring dialysis or any medical condition including chronic liver disease (Child Pugh Score A, B, or C), which in the Investigator's opinion, warrants exclusion
- •Study participant is currently participating in another study of an investigational medication (or a medical device) other than brivaracetam (BRV). The use of antiepileptic drugs (AEDs) marketed for adults but not approved for pediatric use is not considered to be "investigational" for the purposes of this study
- •Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the Investigator or medical monitor, contraindicates participation in the study
- •Exclusion criteria for long-term follow-up (LTFU) study participants only
- •Study participant had poor compliance with the visit schedule or medication intake in the BRV core study
- •Study participant >= 6 years of age has a lifetime history of suicide attempt (including an actual attempt, interrupted attempt, or aborted attempt), or has suicidal ideation in the past 6 months as indicated on the Columbia Suicide Severity Rating Scale (C-SSRS)
- •Exclusion criteria for directly enrolled (DE) study participants only
- •Study participant has a history of primary generalized epilepsy
- •Study participant has a history of status epilepticus in the 30 days immediately prior to the Screening Visit (ScrV) or during the Screening Period
- •Study participant has history or presence of known psychogenic nonepileptic seizures
- •Study participant has experienced febrile seizures exclusively. The occurrence of febrile seizures in addition to other unprovoked seizures is not exclusionary
- •Study participant has any clinically significant acute or chronic illness as determined during the physical examination or from other information available to the Investigator (eg, bone marrow suppression, chronic hepatic disease, severe renal impairment, psychiatric disorder as per Investigator assessment)
- •Study participant has clinically significant laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results, according to the judgment of the Investigator
- •Study participant has a clinically significant ECG abnormality according to the Investigator
- •Study participant had major surgery within 6 months prior to the ScrV
研究者
相似试验
已完成
1 期
A programme to develop a skin patch containing two medicines (physostigmine and hyoscine), Study 6: Assessment of blood levels of the two medicines and any associated symptoms in healthy female participants.ISRCTN15358284Dstl36
进行中（未招募）
不适用
A study investigating the safety and tolerability of deferiprone in patients with Friedreich's Ataxia - NDpatients affected by Friedreich AtaxiaMedDRA version: 9.1Level: LLTClassification code 10017374Term: Friedreich's ataxiaEUCTR2007-003331-23-ITAPOPHARMA INC., TORONTO, ONTARIO80
进行中（未招募）
不适用
A study to investigate the safety and tolerability of intravenous QEQ278 in patients with advanced solid tumorsjRCT2031220585Novartis Pharma. K.K.9
已完成
1 期
A study to investigate the safety and tolerability of dostarlimab in adult participants with chronic HBV infection on nucleos(t)ide analogue (NA) treatment2023-509027-41-00Glaxosmithkline Research & Development Limited23
进行中（未招募）
1 期
A pilot study to assess the safety, tolerability, dose finding and efficacy of ORY-1001 in combination with azacitidine in older patients with AML in first line therapy.Patients with acute mieloyd leukemia (AML)MedDRA version: 20.1Level: LLTClassification code 10024349Term: Leukemia myeloidSystem Organ Class: 100000004864EUCTR2018-000482-36-ESOryzon Genomics S. A.30